文献速递肺栓塞与肺血管病

β受体阻滞剂对不同合并症状态的肺动脉高压患者结局的影响:波兰人群多中心前瞻性队列研究

Effects of β-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study: The Database of Pulmonary Hypertension in the Polish Population (BNP-PL).
PubMed 文献 · Chest · 2024-11-09

基于波兰肺动脉高压数据库(BNP-PL)806例新诊断PAH患者的前瞻性队列分析,58.2%在诊断时使用β受体阻滞剂。无合并症患者中复合终点不良影响更明显。

要点

  • 新诊断PAH患者使用β受体阻滞剂与复合终点风险升高相关(HR 1.44)。
  • β受体阻滞剂对全因死亡影响中性(HR 1.22,95%CI 0.87-1.72)。
  • 无高血压、冠心病或心律失常合并症者使用β受体阻滞剂风险更突出。

核心结论

  • β受体阻滞剂在PAH患者中尤其无系统性高血压、冠心病或心律失常合并症者可能带来显著风险。

研究设计与样本

  • 多中心前瞻性队列研究,纳入波兰肺动脉高压数据库(BNP-PL)806例新诊断PAH患者。
  • 采用倾向评分匹配基于年龄、PAH死亡风险变量和初始PAH特异性治疗构建对照组。

主要发现

  • 806例中469例(58.2%)在PAH诊断时接受β受体阻滞剂。
  • 按合并症分层,无合并症患者中β受体阻滞剂对复合终点显示不良影响,至少一种合并症患者中为中性效应。

关键数值与推荐

  • β受体阻滞剂使用指征包括高血压、显著心律失常和冠状动脉疾病。
  • 复合终点为右心衰竭住院、晕厥或死亡的组合。

临床怎么用

  • 新诊断PAH患者处方β受体阻滞剂需谨慎评估合并症指征,尤其无高血压、冠心病或心律失常者可能增加复合终点风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines do not recommend β-blockers in pulmonary arterial hypertension (PAH) unless indicated by comorbidities. However, the evidence regarding the role of β-blockers in PAH is contradictory. RESEARCH QUESTION: What are the effects of β-blockers on clinical outcomes in patients newly diagnosed with PAH, and how do these outcomes differ based on the presence of cardiovascular comorbidities that are standard indications for β-blocker use? STUDY DESIGN AND METHODS: We analyzed data from 806 patients newly diagnosed with PAH enrolled prospectively in the Database of Pulmonary Hypertension in the Polish Population (BNP-PL). The end points were all-cause mortality and a composite of hospitalization due to right-sided heart failure, syncope, or death. Indications for β-blocker use included hypertension, significant arrhythmia, and coronary artery disease. Propensity score matching was used to form a control group based on age, PAH mortality risk variables, and initially introduced PAH-specific therapy. RESULTS: Of the 806 patients, 469 (58.2%) received β-blockers at the time of PAH diagnosis. In propensity score matching, β-blocker treatment showed a higher incidence of the composite end point (hazard ratio, 1.44; 95% CI, 1.04-1.99; P = .03) and had a neutral impact on mortality (hazard ratio, 1.22; 95% CI, 0.87-1.72; P = .25). When stratified according to the presence of comorbidities, β-blockers showed adverse effects on the composite end point in patients without comorbidities and a neutral effect in patients with at least one comorbidity. INTERPRETATION: Our results indicate that β-blockers pose significant risks in patients with PAH, especially in patients without coexisting systemic hypertension, coronary artery disease, or arrhythmia. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03959748; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Waligóra M, Kurzyna M, Mularek-Kubzdela T, et al. Effects of β-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study: The Database of Pulmonary Hypertension in the Polish Population (BNP-PL). Chest. 2024. PMID: 39528108. doi:10.1016/j.chest.2024.10.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。